Samsung Bioepis gets FDA OK for its interchangeable biosimilar

Samsung Bioepis gets FDA OK for its interchangeable biosimilar

Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official design...

Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...

Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz

Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz

Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...

Kakao Pay backs out of acquisition deal for SSG Pay, Smile Pay Hanwha in talks to buy five-star hotel Paraspara Seoul Kia's Lego-like PV5 with 16 variants to hit market in July Stray Kids make K-pop history with landmark stadium show in Germany S.Korea’s most prominent business leader returns with all charges cleared
banner